#Access to medicines1

Affordable twice-yearly HIV injection lenacapavir to reach 120 countries

Lenacapavir, a twice-yearly HIV prevention injection, will be licensed for 120 low- and middle-income countries at US$40 a year. Rollout is expected from 2027 with funding support, but some countries and price transparency remain concerns.

Photo by Spencer Davis, Unsplash